当前位置： SCI文献检索 > Deutsches Arzteblatt International期刊下所有文献 > Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.

Abstract：

BACKGROUND:Multiple sclerosis (MS) is the most common autoimmune disease of the central nervous system. There are at least 150 000 persons with MS in Germany. Recent years have seen the approval of new drugs against. METHODS:This article is based on pertinent literature retrieved by a selective search in PubMed as well as on documentation of relevant risks and adverse effects in "red hand letters" (information bulletins from pharmaceutical companies to physicians about adverse drug effects) and elsewhere, along with data provided by the German Multiple Sclerosis Competence Network. RESULTS:In recent years, there have been major advances enabling better, more individualized treatment of patients with MS. Physicians must, however, give due consideration to potentially severe or even life-threatening adverse drug effects. These can include, for example, transaminase elevation (hepatotoxicity), cardio- and nephrotoxicity, or lympho- and leukopenia with a variable risk of infection. Among patients taking natalizumab, the cumulative risk of developing progressive multifocal leukencephalopathy (PML) may be 1:100 or higher, depending on the individual risk profile. Rare cases of PML have also been seen under treatment with fingolimod and dimethyl fumarate. Moreover, any type of immunosuppressive treatment can, at least theoretically, increase the risk of malignant disease. Secondary autoimmune diseases can arise as well: approximately 35% of patients treated with alemtuzumab develop autoimmune thyroid disease within two years, and 2% of patients who take daclizumab have severe autoimmune dermatological side effects. Teriflunomide, fingolimod, natalizumab, mitoxantrone, interferon β1-a/b, and daclizumab can all damage the liver. There are also psychiatric, reproductive, and vaccineassociated risks and side effects that must be considered. CONCLUSION:Newer drugs for MS have enabled more effective treatment, but are also associated with a higher risk of side effects. Interdisciplinary risk management is needed.

journal_name

Dtsch Arztebl Int

journal_title

Deutsches Arzteblatt international

authors

Havla J,Warnke C,Derfuss T,Kappos L,Hartung HP,Hohlfeld R

doi

10.3238/arztebl.2016.0879

subject

Has Abstract

pub_date

2016-12-26 00:00:00

pages

879-886

issue

51-52

issn

1866-0452

pii

arztebl.2016.0879

journal_volume

113

pub_type

杂志文章,评审

在线工具

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.